BioPharmSignal logoBioPharmSignal

Biotech News

CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026

CytomX Therapeutics, Inc. (CTMX)CytomX Therapeutics, Inc.Earnings

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close

Related news

CTMXCytomX Therapeutics, Inc.2026-11-05 21:15 EST

CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

URGNUroGen Pharma2026-10-27 22:00 EST

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

View all latest news

CytomX Therapeutics, Inc.

Conditionally Activated Biologics CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates. Varsetatug Masetecan Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY...

Recent company news

CTMXCytomX Therapeutics, Inc.2026-11-05 21:15 EST

CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-11-02 13:00 EST

CytomX Therapeutics to Present at Upcoming November Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-10-29 12:00 EST

CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026

CTMXCytomX Therapeutics, Inc.2026-09-01 12:00 EST

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-08-27 12:00 EST

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

Stock data

Close
2.14 USD
Market cap
687.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States